Engflag

Koffein

Quick links to important sections

Koffein

Koffein_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Koffein

What is Koffein?

Koffein, known internationally as caffeine, is a naturally occurring alkaloid belonging to the methylxanthine class. It is found in the seeds, fruits, or leaves of over sixty plants, including coffee beans, tea leaves, cocoa beans, and guarana berries. In its pure form, it is a white, bitter-tasting crystalline powder.

Mechanism of Action

Koffein acts primarily as a central nervous system stimulant. Its biological effect is largely attributed to its role as an adenosine receptor antagonist. In the brain, adenosine is a neurotransmitter that promotes sleep and relaxation by binding to specific receptors. Because koffein has a similar molecular structure to adenosine, it can bind to these receptors without activating them, effectively blocking the signals that signal fatigue.

Physical and Cognitive Effects

When koffein enters the system, it influences various physiological processes:

  • Alertness: By inhibiting adenosine, it helps maintain a state of wakefulness and can temporarily reduce the sensation of tiredness.
  • Metabolic Rate: It can cause a slight increase in metabolic rate and stimulate the release of epinephrine (adrenaline).
  • Circulatory System: It may lead to a temporary increase in heart rate and blood pressure due to its stimulating effect on the cardiovascular system.
  • Cognitive Function: Many individuals use it to support concentration, focus, and short-term memory during tasks that require sustained mental effort.

Common Sources

Koffein is most frequently consumed through beverages and food products. The concentration of the substance varies depending on the source and the method of preparation:

  • Coffee: Generally contains the highest concentration per serving among common beverages.
  • Tea: Contains koffein along with theophylline and L-theanine, which can modify the rate of absorption.
  • Soft Drinks and Energy Drinks: Often contain added synthetic koffein.
  • Chocolate: Contains small amounts of koffein naturally present in the cocoa bean.

In a clinical or pharmaceutical context, koffein is sometimes used as an adjuvant in specific formulations to modify the effects of other substances, particularly in the management of headaches or to support respiratory function in specific neonatal cases.

Regulatory References

  1. Caffeine Citrate on WHO Essential Medicines List
  2. Caffeine - MedlinePlus

What side effects are possible with Koffein?

Officially Documented Adverse Reactions

The safety profile of Koffein, which contains the active substance Caffeine, is primarily characterized by effects linked to its action as a central nervous system stimulant. The officially documented adverse reactions are categorized by the body system affected, consistent with regulatory classifications.

System-Organ Classes Affected

Adverse reactions are frequently reported across several system-organ classes, based on governmental regulatory documents:

  • Nervous System Disorders: Reactions such as insomnia, nervousness, restlessness, tremor, and headache are commonly cited.
  • Cardiac Disorders: Palpitations and tachycardia (rapid heartbeat) are documented.
  • Gastrointestinal Disorders: These effects include nausea, vomiting, and diarrhea.

Serious Adverse Reactions and Toxicity

High-level regulatory sources document that more severe adverse reactions, such as seizures and ventricular arrhythmias, are typically associated with very high serum concentrations and instances of toxicity or overdose. In the specific context of use for premature infants, close monitoring is required regarding the risk of necrotizing enterocolitis.

Safety Considerations in Specific Populations

Regulatory documentation mandates specific cautions for certain populations. Individuals with pre-existing cardiovascular disease require caution due to the documented effects on heart rate. In preterm neonates, especially those with existing impaired renal or hepatic function, serum concentrations must be carefully monitored to manage the risk of toxicity. The product is formally contraindicated in patients with a known hypersensitivity to any of its components.

Safety Notes on Time-Related Patterns

The official safety profile recognizes that the body may develop tolerance to some physiological effects, such as increased blood pressure, with chronic use. Conversely, withdrawal symptoms (e.g., headache, sleepiness) are documented as potential outcomes following the abrupt cessation of regular daily intake.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Koffein

Overdose Scope

Property Official Regulatory Documentation
Documented Overdose Presentations: CNS hyperexcitability, including tremors, agitation, confusion, and progression to stupor; significant Cardiovascular Instability (tachycardia, palpitations, arrhythmias); severe gastrointestinal distress (vomiting, diarrhea); and systemic effects such as fever.
Physiological Systems Affected (as stated in label): Central Nervous System (CNS), Cardiovascular System, Gastrointestinal System, Metabolic System.
Dose-related or exposure-related factors (if applicable): Ingestion of smaller doses can be life-threatening in children or other sensitive populations.
Population-specific overdose notes (if applicable): Newborns/Infants are at increased risk due to slow elimination. Plasma concentration monitoring may be required.
Emergency-response statements (as written in official documents): Contact the local Poison Control Center. Do NOT induce vomiting unless instructed by a healthcare provider.
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention in the event of overdosage, even if the individual appears asymptomatic. Go to the emergency room or call 911 (or local emergency services number).

Overdose Classifications (High-Level)

Property Official Regulatory Documentation
Severity classification (as defined in official documents): Overdose can progress to severe and life-threatening toxicity, including seizures, coma, and cardiac arrest.
Regulatory basis (EMA / FDA / etc.): Information is based on official documents from multiple government agencies.
Overdose-context constraints (as defined in official documents): Treatment is strictly symptomatic and supportive. No specific antidote is listed in regulatory summaries.

Resulting Overdose Structure

Official Overdose Statements:

  • Regulatory documents define overdose by severe manifestations including seizures and life-threatening ventricular fibrillation or cardiac arrest, alongside metabolic disturbances such as anion gap metabolic acidosis.
  • The required emergency action is to seek immediate medical attention immediately upon suspected overexposure, regardless of current symptoms.
  • Documented procedural steps for management include the administration of activated charcoal, the use of benzodiazepines for seizure control, and the potential need for hemodialysis in severe cases.
  • Hospital monitoring requirements include measurement of vital signs, ECG, and monitoring of serum caffeine levels to guide intervention.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Koffein overdose profile by the escalation of CNS and cardiovascular hyperstimulation, identifying seizures and cardiac arrhythmias as the most severe, life-threatening outcomes. This established risk dictates the required emergency action, which strictly mandates that a user seek immediate medical attention and contact emergency services, emphasizing the necessity of rapid hospital intervention focused on symptomatic and supportive care.

Therapeutic Uses of Koffein

Koffein, which contains the active substance Caffeine, is commonly used to help manage symptoms related to both generalized exhaustion and highly specific medical conditions. It is primarily used for the short-term relief of fatigue and drowsiness in adults seeking to support mental alertness.

Managing Situational Drowsiness and Mental Fatigue

Koffein is commonly used to help manage symptom clusters that may become intense or disruptive and create noticeable functional strain, such as drowsiness and reduced mental alertness. The application of Koffein is associated with symptomatic relief across domains, including temporary fatigue and supporting alertness during periods of extended wakefulness. Applied in contexts where short-term symptomatic assistance is needed, it supports patients by providing relief that may assist with maintaining the capacity for sustained mental effort.

Supportive Clinical Uses

In appropriate clinical settings, Koffein is applied across domains where additional symptomatic support is needed. It is considered relevant for easing symptomatic discomfort associated with specific acute episodes like post-dural puncture headache (PDPH), and it is relevant for managing the symptomatic manifestations of apnea of prematurity in premature infants. It is applied in scenarios where symptoms create noticeable functional strain, requiring temporary symptomatic stabilization.

Therapeutic Summary

Symptom Domain Primary Benefit
Situational Drowsiness Helps ease symptoms that interfere with alertness
Fatigue/Exhaustion Contributes to maintaining capacity for mental effort
Apnea of Prematurity May assist with managing symptomatic manifestations

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official eligibility profile for Koffein (Caffeine) is defined by regulatory bodies based on age, clinical status, and underlying comorbidities. Use is permitted for Adults for the temporary relief of fatigue and drowsiness (OTC use). Conversely, it is generally not recommended for general use in Children and Adolescents.

Eligibility Restrictions

Use is contraindicated in patients with a known hypersensitivity to the substance. Furthermore, high-dose use is prohibited for individuals with certain severe, uncontrolled cardiovascular disorders, such as severe cardiac arrhythmias.

Use requires caution or is restricted in several populations, including those with:

  • Severe Hepatic or Renal Impairment, due to the potential for the substance to accumulate.
  • A history of seizure disorders or gastrointestinal ulcers.

Pregnancy and Lactation: Use is generally restricted or not recommended. Caffeine is excreted into breast milk and may affect the infant; official guidance often recommends limiting intake during these periods.

Special Population: The medicine is permitted for the specific clinical treatment of apnea of prematurity in premature infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Koffein (Caffeine) details constraints primarily related to its metabolism and central nervous system (CNS) effects. These constraints define three main domains for interaction management: cumulative stimulant effects, metabolic inhibition, and pharmacodynamic antagonism.

Documented Interaction Domains

Interaction Domain Practical Constraint Defined by Regulators
Cumulative Stimulant Effects Avoid co-administration with other caffeine-containing products (foods, beverages, health products), particularly when total daily intake reaches or exceeds 400 mg.
CYP1A2 Inhibition Co-administration must be assessed for drugs that are CYP1A2 substrates, as Koffein acts as an inhibitor of this enzyme, which can alter the substrate drug's exposure.
Pharmacodynamic Antagonism The use of high-caffeine products is restricted with substances like alcohol or should be managed carefully with CNS depressant drugs due to opposing or synergistic effects.

Population- and Condition-Specific Notes

The product labeling contains specific advice for certain groups, particularly restricting use for individuals with pre-existing conditions such as high blood pressure or glaucoma when consuming products providing over 400 mg of caffeine daily. A consultation with a health professional is advised for those who are pregnant, breastfeeding, or attempting to conceive if the total daily intake of caffeine exceeds 300 mg.

Mechanism of Action

Dominant Antagonism of Inhibitory Adenosine Signals

The dominant mechanism of Caffeine involves its action as a competitive antagonist at A1 and A2A Adenosine Receptors in the brain. By structurally mimicking the inhibitory neuromodulator Adenosine, the drug blocks its binding site, effectively removing the inhibitory brake on neuronal activity. This disinhibition rapidly leads to increased neuronal excitability and accelerated central nervous system activity and metabolism across the CNS.

Indirect Sympathomimetic and Vascular Modulation

The widespread CNS stimulation caused by Adenosine receptor blockade triggers a cascade that indirectly increases the release of Norepinephrine and Epinephrine (Adrenaline) from sympathetic centers. This augmented release contributes to increased heart rate and force of cardiac contraction. Simultaneously, the blockade of Adenosine Receptors on cerebral blood vessels causes local vasoconstriction, which modulates blood flow and is a significant physiological consequence of the drug's action outside of direct stimulation.

High-Concentration Enzyme Inhibition and Calcium Release

At higher physiological concentrations, Caffeine also acts as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes. By blocking the breakdown of intracellular messengers like cyclic AMP (cAMP), this secondary mechanism modulates smooth muscle tone, notably in the bronchial system. This pathway, along with its ability to induce intracellular calcium release at very high levels, contributes to the overall spectrum of dose-dependent physiological changes.

Dosage and Administration Information

Koffein is administered via two primary protocols: a fixed-dose oral regimen for general use and a weight-based intravenous/oral regimen for specific clinical indications.

Administration Scope

The oral route is used for solid forms, typically available as tablets or capsules. For adult use, a standard single dose is 100 mg to 200 mg of anhydrous caffeine. This dose may be repeated intermittently, with a mandatory interval of no less than 3 to 4 hours between doses. The product is generally restricted for use in persons 12 years of age and older.

In clinical settings, the medicine is administered as Caffeine Citrate Injection or Oral Solution for use in premature infants (28 to <33 weeks gestational age). The clinical protocol involves a single intravenous loading dose of 20 mg/kg, which must be infused slowly over 30 minutes. This is followed 24 hours later by a maintenance dose of 5 mg/kg/day, which can be given intravenously or orally. The maintenance dose is administered once daily.

Procedural Conditions

Solutions intended for infusion must be visually inspected prior to administration. Preservative-free single-use vials must be discarded after the required dose is withdrawn. Dose adjustments and monitoring of serum concentrations are required for patients with documented renal or hepatic impairment.

Recent Clinical Evidence

Koffein: Recent Clinical Evidence

Recent clinical evidence continues to support the established uses and investigate new therapeutic applications for caffeine, a central nervous system stimulant. The compound is officially approved for the treatment of apnea of prematurity in premature infants, where it acts as a respiratory stimulant. Further trials have also evaluated its role in the prevention and treatment of bronchopulmonary dysplasia and neurodevelopmental outcomes in this vulnerable population, with promising results regarding improved weight gain and reduced long-term delays. New clinical trials are actively studying the use of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) to assess if it can reduce mortality or neurodevelopmental impairment when given in conjunction with therapeutic hypothermia.

Pain Relief and Neurological Function

In pain management, the addition of caffeine to common analgesics (such as ibuprofen or acetaminophen) is confirmed to modestly improve the proportion of people achieving pain relief from conditions like tension headaches and migraines. Clinically, caffeine is also being explored for its effects on neurological conditions. A small-scale pilot trial suggests that a regular daily dose may enhance balance, functional mobility, and quality of life for individuals with Multiple Sclerosis (MS). Similarly, some clinicians have utilized it off-label to manage orthostatic hypotension and enhance physical and cognitive performance.

Cardiovascular and Safety Considerations

The established safety guideline for most healthy adults is a daily intake of up to 400 mg of caffeine. However, recent studies highlight that chronic consumption at or above this level may significantly impact the autonomic nervous system, potentially leading to elevated heart rates and blood pressure over time, which may heighten the susceptibility to cardiovascular disease. Researchers are also exploring the clinical significance of Caffeine Use Disorder, noting that even moderate intake can lead to problematic patterns of use, withdrawal symptoms, anxiety, or insomnia in a subset of the population, suggesting the need for awareness and potential reduction strategies for some individuals.

Frequently Asked Questions (FAQ)

Common questions about Koffein (FAQ)

Q: What is the maximum daily dose of Koffein I can take?

Regulatory documents state that for general adult use, single doses for over-the-counter (OTC) products have a standard suggested limit in the label information. Official information also advises that the total daily intake from all sources—including foods, beverages, and other health products—should be carefully managed, with caution generally advised against exceeding 400 mg daily.

Q: What are the symptoms of Koffein withdrawal?

Regulatory documentation recognizes that the body can develop a dependence on regular daily intake. If use is abruptly stopped, withdrawal symptoms may occur. These symptoms commonly documented in official information include experiencing a headache, feeling fatigue, being irritable, and drowsiness.

Q: Can I use Koffein if I have a pre-existing medical condition like a seizure disorder?

Official product information advises caution for individuals who have a history of seizures or other seizure disorders. Use is also restricted for individuals with certain severe, uncontrolled cardiac arrhythmias. Individuals with a pre-existing medical condition, such as those listed, are advised to consult a healthcare professional.

Q: How long does it take for Koffein to start working after taking a dose?

Studies and official information indicate that Koffein is generally absorbed rapidly after oral use. The concentration of the drug in the bloodstream typically reaches its maximum level, or peak effect, approximately 30 to 60 minutes after ingestion. This time frame represents the point at which the drug is expected to reach its highest concentration.

Q: Does Koffein make you dehydrated?

Koffein is known to possess a mild diuretic effect, meaning it can increase the production of urine. However, when consumed as a beverage, the liquid in the drink itself usually balances this effect. The available product information does not commonly classify it as a significant dehydrating agent.

Q: Can I take a missed dose of Koffein, and if so, when?

For over-the-counter (OTC) products intended to relieve drowsiness, the regulatory guidance is to take the product only when needed and to maintain the required time interval between doses. If taking a prescription form of Koffein, especially for a clinical indication, it is recommended to contact the prescribing healthcare provider for specific instructions regarding a missed dose.

How should Koffein be stored and disposed of?

How to Store and Dispose of Koffein

Official Storage Requirements

Requirement Domain Official Regulatory Statement
Temperature & Environment Store oral solid forms away from heat and moisture at controlled room temperature (e.g., 68 F–77 F); specific solution forms may require no special storage conditions.
Container Integrity The medicine must be kept in its original container and the container must be kept tightly closed.
Child Protection A mandated requirement is to keep the medicinal product out of the reach and sight of children.
Stability Certain solution preparations are designated for single use only, requiring that any unused solution be discarded immediately after use.

Official Disposal Instructions

Unused medicinal product or waste materials must be disposed of in accordance with local requirements. The official procedures include utilizing a drug take-back program or following specific governmental steps for household trash disposal. When disposing of the product in household trash, the medicine must be mixed with an unappealing substance, and all identifying information on the label must be removed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Koffein found in:

A-Z Index: